NATICK, Mass., Jan. 19, 2011 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced that its subsidiary, Boston Scientific Japan K.K., has reached an agreement with Fukuda Denshi Co., Ltd. to market and sell its cardiac rhythm management (CRM) devices and accessories throughout Japan.  Fukuda Denshi's extensive sales resources, distribution network and service capabilities will complement Boston Scientific's existing sales and marketing organization and allow the Company to reach substantially more accounts and expand the service it offers to its customers in Japan.  Fukuda Denshi will begin distributing Boston Scientific CRM products this quarter.

"We are pleased to reach agreement with Fukuda Denshi to distribute our CRM products in Japan," said Maulik Nanavaty, President of Boston Scientific Japan.  "Our enhanced sales, distribution and service capabilities will help us better serve Japanese physicians and their patients while broadening our reach and growing our market share in this important market.  Fukuda Denshi has been an established player in Japan for more than 70 years, with a proven track record and a long and successful history of delivering results.  We look forward to a successful partnership with them."

Boston Scientific is a leading developer of implantable devices used to treat cardiac arrhythmias (abnormal heart rhythms), sudden cardiac arrest and heart failure.  The Company's advanced product portfolio includes pacemakers, implantable cardioverter defibrillators (ICDs), cardiac resynchronization therapy defibrillators (CRT-Ds), cardiac leads and patient management systems.

About Fukuda Denshi

Founded in 1939, Fukuda Denshi is a global leader in the research and development, manufacture and sale of medical electronics equipment.  With corporate headquarters in Tokyo, the company supports direct sales and distributor networks globally.  Its annual revenues exceed $1 billion.

About Boston Scientific

Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties.  For more information, please visit: www.bostonscientific.com.  

Cautionary Statement Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934.  Forward-looking statements may be identified by words like "anticipate," "expect," "project," "believe," "plan," "estimate," "intend" and similar words.  These forward-looking statements are based on our beliefs, assumptions and estimates using information available to us at the time and are not intended to be guarantees of future events or performance.  These forward-looking statements include, among other things, statements regarding new product launches and launch cadence, regulatory approvals, clinical trials, product performance and competitive offerings.  If our underlying assumptions turn out to be incorrect, or if certain risks or uncertainties materialize, actual results could vary materially from the expectations and projections expressed or implied by our forward-looking statements.  These factors, in some cases, have affected and in the future (together with other factors) could affect our ability to implement our business strategy and may cause actual results to differ materially from those contemplated by the statements expressed in this press release.  As a result, readers are cautioned not to place undue reliance on any of our forward-looking statements.  

Factors that may cause such differences include, among other things: future economic, competitive, reimbursement and regulatory conditions; new product introductions; demographic trends; intellectual property; litigation; financial market conditions; and future business decisions made by us and our competitors.  All of these factors are difficult or impossible to predict accurately and many of them are beyond our control.  For a further list and description of these and other important risks and uncertainties that may affect our future operations, see Part I, Item 1A – Risk Factors in our most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission, which we may update in Part II, Item 1A – Risk Factors in Quarterly Reports on Form 10-Q we have filed or will file hereafter.  We disclaim any intention or obligation to publicly update or revise any forward-looking statements to reflect any change in our expectations or in events, conditions or circumstances on which those expectations may be based, or that may affect the likelihood that actual results will differ from those contained in the forward-looking statements.  This cautionary statement is applicable to all forward-looking statements contained in this document.

SOURCE Boston Scientific Corporation